Experienced in Acquired Hemophilia

Dr. Michael C. Wang

Psychiatry
1200 N State St, 
Los Angeles, CA 
Experienced in Acquired Hemophilia
1200 N State St, 
Los Angeles, CA 
OverviewInsuranceLocationsClinical Research

Overview

Michael Wang is a Psychiatrist in Los Angeles, California. Dr. Wang is rated as an Experienced provider by MediFind in the treatment of Acquired Hemophilia. His top areas of expertise are Acquired Hemophilia and Venous Thromboembolism (VTE).

His clinical research consists of co-authoring 129 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Acquired Hemophilia.

Specialties
Psychiatry
Licenses
Psychiatry & Neurology in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

1200 N State St, Los Angeles, CA 90089

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII) in Severe Hemophilia A Subjects Administered a Single Intravenous Infusion
A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII) in Severe Hemophilia A Subjects Administered a Single Intravenous Infusion
Enrollment Status: Completed
Publish Date: September 11, 2025
Intervention Type: Drug
Study Drug: BAX-888 Adeno-Associated Virus Serotype 8 Vector B-Domain Deleted Factor VIII Vaccine
Study Phase: Phase 1/Phase 2
A Phase 3b, Prospective, Open-Label, Uncontrolled, Multicenter Study on Long-Term Safety and Efficacy of rVWF in Pediatric and Adult Subjects With Severe Von Willebrand Disease (VWD)
A Phase 3b, Prospective, Open-Label, Uncontrolled, Multicenter Study on Long-Term Safety and Efficacy of rVWF in Pediatric and Adult Subjects With Severe Von Willebrand Disease (VWD)
Enrollment Status: Completed
Publish Date: September 03, 2025
Intervention Type: Biological
Study Drugs: Von Willebrand Factor, Factor VIII
Study Phase: Phase 3
ATHN 9: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Severe Von Willebrand Disease (VWD)
ATHN 9: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Severe Von Willebrand Disease (VWD)
Enrollment Status: Active_not_recruiting
Publish Date: March 12, 2025
US Cohort Study of Previously Untreated Patients (PUPs) With Congenital Hemophilia
US Cohort Study of Previously Untreated Patients (PUPs) With Congenital Hemophilia
Enrollment Status: Completed
Publish Date: February 01, 2023
A Phase III Study on the Safety, Pharmacokinetics, and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Pediatric Patients From Birth to <12 Years Old With Inhibitors to Factor VIII or IX: PerSept 2
A Phase III Study on the Safety, Pharmacokinetics, and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Pediatric Patients From Birth to <12 Years Old With Inhibitors to Factor VIII or IX: PerSept 2
Enrollment Status: Completed
Publish Date: February 25, 2022
Intervention Type: Biological
Study Phase: Phase 3
A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Factor Replacement Products
A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Factor Replacement Products
Enrollment Status: Completed
Publish Date: December 09, 2021
Intervention Type: Biological
View 5 Less Clinical Trials

129 Total Publications

CSF proteogenomics implicates novel proteins and humoral immunity in Alzheimer's disease risk.
CSF proteogenomics implicates novel proteins and humoral immunity in Alzheimer's disease risk.
Journal: medRxiv : the preprint server for health sciences
Published: October 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wang's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile